RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) "Relief" is a biopharmaceutical company whose objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need. We focus on clinical-stage programs based on molecules with a history of clinical use (well-established safety and tolerability) and either initial human activity or efficacy data (proof of concept) or a strong scientific rationale. This allows us to identify molecules where clinical development can be swift (trials with evaluation windows of weeks or months) and cost effective. Our lead compound is RLF-100™, a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action, for respiratory indications. The development program currently is focused on COVID-19-induced severe lung injury and pulmonary sarcoidosis. These are two diseases for which an unmet medical need exists. Clinical development opportunities of RLF-100™ for other indications in both acute and chronic lung diseases are being evaluated. In addition, Relief recently acquired rights for certain territories, including Europe, for the development and commercialization of ACER-001, a proprietary powder formulation of sodium phenylbutyrate (NaPB) designed to be both taste-masked and immediate release. ACER-001 is being developed for the treatment of two rare and debilitating diseases, Urea Cycle Disorders and Maple Syrup Urine Disease. RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.